Doctors Note Logo

Published on: 4/29/2026

Why Medicare Denies PRP? The Scientific Reality & Your Approved Next Steps

Medicare labels PRP therapy experimental because there is no national coverage determination, CMS finds the clinical evidence mixed, and unstandardized coding leads to routine denials for musculoskeletal and soft-tissue injections.

You can still pursue coverage by discussing alternatives with your doctor, requesting a letter of medical necessity, filing an appeal, joining clinical trials or exploring complementary therapies.

See below for crucial scientific data, local coverage rules and step-by-step guidance that could shape your next steps.

answer background

Explanation

Why Medicare Denies PRP: The Scientific Reality & Your Approved Next Steps

Platelet-rich plasma (PRP) therapy has surged in popularity for treating joint pain, tendon injuries and certain degenerative conditions. Yet many Medicare patients find their claims denied. This guide explains why Medicare considers PRP "experimental," reviews the scientific data and offers practical next steps—without creating anxiety.


What Is PRP Therapy?

PRP involves drawing a small amount of your blood, spinning it in a centrifuge to concentrate platelets and injecting that platelet-rich mixture into injured tissues. Platelets contain growth factors that may help heal tendons, ligaments, muscles and joints. Common uses include:

  • Knee osteoarthritis
  • Tennis elbow
  • Rotator cuff tendinopathy
  • Achilles tendinopathy

PRP is generally safe, using your own blood and avoiding steroids. However, its coverage under Medicare remains limited.


Why Medicare Denies PRP for Medicare Patients

  1. Lack of National Coverage Determination (NCD)

    • Medicare's NCDs outline services considered "reasonable and necessary."
    • As of now, there is no NCD approving PRP for musculoskeletal or soft-tissue injuries. Without this, PRP is deemed experimental and not covered.
  2. Classification as "Investigational"

    • CMS (Centers for Medicare & Medicaid Services) labels PRP investigational due to mixed results in clinical studies.
    • Investigational treatments generally do not meet coverage criteria.
  3. Insufficient High-Level Evidence

    • Medicare requires robust, large-scale, randomized controlled trials (RCTs) demonstrating clear benefit.
    • Many PRP studies are small, use different preparation methods and have short follow-up periods.
  4. Coding and Billing Complexities

    • PRP injections often use unlisted procedure codes (e.g., CPT 0232T), triggering denials or requests for more information.
    • Lack of standardized coding makes it harder to secure coverage.
  5. Local Coverage Determinations (LCDs)

    • Some Medicare Administrative Contractors (MACs) issue LCDs on PRP. Most currently deny it for musculoskeletal conditions.
    • Even when an LCD allows PRP in limited cases, strict criteria must be met (e.g., refractory to conventional treatments).

The Scientific Reality: What the Research Shows

Medicare's hesitancy rests on the quality and consistency of published data:

  • Positive Signals

    • Knee osteoarthritis: Several small RCTs report pain relief and improved function at 6–12 months.
    • Tendon injuries: Some trials show faster recovery compared to placebo or corticosteroids.
  • Limitations

    • Small Sample Sizes: Many studies enroll under 100 patients per group.
    • Variable Protocols: Differences in platelet concentration, injection frequency and guidance (ultrasound vs. blind).
    • Short Follow-Up: Most trials track outcomes for less than 1 year.
    • Heterogeneous Patient Groups: Mixing mild and severe cases makes it hard to define who benefits most.
  • CMS Requirements

    • Consistent, multi-site RCTs with standardized PRP preparation.
    • Long-term safety data beyond 12 months.
    • Clear patient selection criteria (age, severity, comorbidities).

Until large, well-designed trials address these gaps, Medicare will likely maintain its "experimental" stance.


Your Approved Next Steps

Even if Medicare initially denies PRP, you have options:

  1. Discuss with Your Doctor

    • Review your diagnosis, previous treatments and overall health.
    • Ask whether PRP is medically reasonable in your case or if alternatives (e.g., physical therapy, hyaluronic acid injections) might work.
  2. Request a Written "Letter of Medical Necessity"

    • Your physician can outline why PRP is essential for you, citing your history and any supportive studies.
    • Submit it with your appeal to Medicare.
  3. File an Appeal

    • Follow Medicare's five-step appeals process: redetermination, reconsideration, hearing and up to federal court if needed.
    • Keep organized records: dates of service, provider notes, denial letters and your letter of medical necessity.
  4. Explore Clinical Trials

    • Consider participating in a registered clinical trial. Costs may be covered by the study sponsor.
    • Trials help generate the evidence Medicare needs.
  5. Check for Local Coverage Exceptions

    • Some MACs may allow PRP for specific conditions under narrow criteria.
    • Your billing team or a knowledgeable provider can review LCDs in your region.
  6. Get Personalized Symptom Guidance

    • If you're experiencing joint pain, tendon discomfort or aren't sure whether PRP is right for your specific symptoms, start with a free Medically approved LLM Symptom Checker Chat Bot to help clarify your condition and understand which treatment options to discuss with your doctor.

Alternative and Complementary Therapies

While pursuing PRP coverage, you may benefit from:

  • Physical Therapy
    • Targeted exercises to strengthen muscles and improve joint stability.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Short-term relief of pain and inflammation.
  • Hyaluronic Acid Injections
    • Viscosupplementation for knee osteoarthritis; some Medicare coverage exists in specific situations.
  • Corticosteroid Injections
    • Effective for short-term pain relief but may weaken tissues with repeated use.

Each option has pros and cons. Discuss these with your healthcare team.


Moving Forward with Confidence

  • Stay Informed: Clinical guidelines evolve as new trials report results.
  • Be Proactive: Document your treatment history, collect medical records and involve your provider in appeals.
  • Know Your Rights: Medicare's appeals system exists to protect you—use it if necessary.
  • Seek Professional Advice: Always talk with your doctor before making decisions about serious or life-threatening conditions.

If you have persistent symptoms, please speak to a doctor right away. Your health deserves careful evaluation by a trained professional. For an initial assessment of your symptoms and to prepare better questions for your doctor visit, use this free Medically approved LLM Symptom Checker Chat Bot today.


Medicare may deny PRP now, but armed with the right information, documentation and professional support, you can explore every avenue to get the care you need.

(References)

  • * Kucharik, M., Kucharik, D., & Kucharik, S. (2023). Medicare Payment for Orthopedic Platelet-Rich Plasma Injections: A Current Landscape Review. *Cureus*, *15*(10), e47455. https://pubmed.ncbi.nlm.nih.gov/37901765/

  • * Smith, J., & Malek, M. (2021). Platelet-rich Plasma for Musculoskeletal Injuries: Medicare Denials and Opportunities for Reimbursement. *Physical Medicine and Rehabilitation Clinics of North America*, *32*(4), 793-802. https://pubmed.ncbi.nlm.nih.gov/34686300/

  • * Moussa, M., Lall, K., & Mansour, A. (2021). Evidence-based approach to the use of platelet-rich plasma in musculoskeletal disorders: a meta-analysis of systematic reviews. *BMC Musculoskeletal Disorders*, *22*(1), 1083. https://pubmed.ncbi.nlm.nih.gov/34949167/

  • * Degen, R. M., & Beavis, A. (2023). Current Evidence and Future Prospects for Platelet-Rich Plasma in Orthopedic Surgery. *Seminars in Musculoskeletal Radiology*, *27*(5), 443-453. https://pubmed.ncbi.nlm.nih.gov/37920409/

  • * Sheu, A., Smith, J., Malek, M., & Shapiro, N. (2021). Regulatory and Ethical Considerations for Autologous Biologics: Platelet-Rich Plasma. *Physical Medicine and Rehabilitation Clinics of North America*, *32*(4), 781-792. https://pubmed.ncbi.nlm.nih.gov/34686299/

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.